Michael Boice

Michael Boice has a diverse and extensive work experience in the biotechnology and pharmaceutical industry. Michael began their career as a Research Associate at Oncothyreon, Inc., where they played a key role in driving the clinical development of oncology drugs through Phase I and Phase II studies. Michael designed and implemented assays to analyze pharmacodynamics endpoints in patient samples and established standard operating procedures for continuous testing.

Boice then joined Myriad RBM, Inc. as a Research Associate, where they worked in a leading multiplexed immunoassay testing laboratory. Michael planned and performed diagnostic Multi-Analyte Profile assays, improved existing protocols, and interpreted results for reporting purposes.

Next, Boice worked at the Memorial Sloan Kettering Cancer Center as a PhD candidate in Cancer Biology and Genetics. Here, they utilized genetic information to identify frequently altered genes in lymphomas.

Boice co-founded Repairogen in 2012, a biotechnology and cosmetics company focused on repairing skin damage caused by environmental factors. Michael successfully secured an exclusive license to commercialize the company's technology as a topical skincare product and raised capital from institutional and non-dilutive sources.

Michael then joined Crown Bioscience, Inc. in various roles, including Associate Director, Director, Senior Director, and Executive Director of Business Development. Michael'sresponsibilities included driving product development, leading business development efforts, and establishing strategic partnerships.

Most recently, Boice worked at Translational Drug Development (TD2) as the VP of Scientific Engagement, where they played a vital role in scientific engagement initiatives.

Starting in 2023, Boice will be joining Certis Oncology Solutions, Inc. as a Scientific Engagement & Key Accounts professional.

Michael Boice completed their education in a chronological manner. Michael obtained a Bachelor of Science (BS) degree in Biochemistry and Molecular Biophysics from the University of Arizona from 2002 to 2005. Following this, they pursued a Doctor of Philosophy (Ph.D.) degree in Pharmacology from the Joan & Sanford I. Weill Medical College of Cornell University, completing it from 2009 to 2014. Later, in 2020, they achieved a Certificate in Financial Accounting from Harvard Business School Online. In addition to their formal education, Michael also obtained several certifications, including Build, PMC Level II, and PMC Level I, from Pragmatic Institute in 2020.